Recurrent Erythema Seen With H. cinaedi Bacteremia

This article originally appeared here.
Share this content:
Recurrent Erythema Seen With <i>H. cinaedi</i> Bacteremia
Recurrent Erythema Seen With H. cinaedi Bacteremia

WEDNESDAY, Feb. 10, 2016 (HealthDay News) -- Recurrent superficial cellulitis-like erythema is associated with Helicobacter cinaedi (H. cinaedi) bacteremia, according to a case report published online Jan. 30 in The Journal of Dermatology.

Yuko Adachi, from the Gifu University Graduate School of Medicine in Japan, and colleagues described the case of an immunocompromised man with recurrent superficial cellulitis-like erythema associated with H. cinaedi bacteremia.

The researchers note that the patient was an 85-year-old male with polymyalgia rheumatica that was treated with prednisone. He complained of painful erythema on his lower legs and on his abdomen and thighs with sudden onset of fever. H. cinaedi was isolated from blood culture and identified in polymerase chain reaction. The symptoms were alleviated in two days with meropenem (1.5 grams per day), and treatment was discontinued after 10 days. Ten weeks after discontinuation of treatment, the patient returned with sudden high fever and painful erythema. H. cinaedi was identified from blood culture. Symptoms were alleviated in two days with meropenem, which was continued for 24 days followed by minocycline for five weeks. No symptom recurrence was seen in one year.

"There are no recommended guidelines for treatment of H. cinaedi infection," the authors write. "Symptoms caused by H. cinaedi resolved after two days of carbapenem therapy. However, as 30 to 60 percent of patients with H. cinaedi infection have recurrent symptoms, long-term use of antibiotics is recommended."

Abstract
Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions



Sign up for myCME e-newsletters




More in Home

FDA Approves Palynziq for Phenylketonuria

FDA Approves Palynziq for Phenylketonuria

Drug is a novel enzyme therapy for adult patients with PKU with uncontrolled blood Phe concentrations

Increase in Tx Candidates With 2017 Hypertension Guidelines

Increase in Tx Candidates With 2017 Hypertension Guidelines

Increase in proportion of adults recommended for treatment; estimated decrease in CVD events, deaths